Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Wardelmann

Showing results (201-210 of 248) with videos related to

Pageof 25
Sort By:
The American Journal of Surgical Pathology|January 15, 2026
Pathologic Assessment of Retroperitoneal Sarcomas: A Position Paper By the Transatlantic Australasian Retroperitoneal Sarcoma Working GroupBibianna Purgina, Elena Di Blasi, Paola Collini, et al.
International Journal of Cancer|February 1, 2018
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Lars H Lindner, Saskia Litière, Stefan Sleijfer, et al.
Cancer Immunology Research|February 13, 2015
Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantationChristoph Schliemann, Katrin L Gutbrodt, Andrea Kerkhoff, et al.
Translational Oncology|August 21, 2018
Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue SarcomaTorsten Kessler, Ariane Baumeier, Caroline Brand, et al.
JAMA Oncology|March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical TrialHeikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
Annals of Hematology|March 24, 2019
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized TrialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
JAMA Oncology|May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-upHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Genome Biology|December 19, 2013
Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomasMarcus Renner, Thomas Wolf, Hannah Meyer, et al.
Cancer Discovery|September 25, 2020
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase DomainSusanne Grunewald, Lillian R Klug, Thomas Mühlenberg, et al.
Pageof 25

Showing results (201-210 of 248) with videos related to

Sort By:
Pageof 25
The American Journal of Surgical Pathology|January 15, 2026
Pathologic Assessment of Retroperitoneal Sarcomas: A Position Paper By the Transatlantic Australasian Retroperitoneal Sarcoma Working GroupBibianna Purgina, Elena Di Blasi, Paola Collini, et al.
International Journal of Cancer|February 1, 2018
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Lars H Lindner, Saskia Litière, Stefan Sleijfer, et al.
Cancer Immunology Research|February 13, 2015
Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantationChristoph Schliemann, Katrin L Gutbrodt, Andrea Kerkhoff, et al.
Translational Oncology|August 21, 2018
Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue SarcomaTorsten Kessler, Ariane Baumeier, Caroline Brand, et al.
JAMA Oncology|March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical TrialHeikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
Annals of Hematology|March 24, 2019
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized TrialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
JAMA Oncology|May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-upHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Genome Biology|December 19, 2013
Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomasMarcus Renner, Thomas Wolf, Hannah Meyer, et al.
Cancer Discovery|September 25, 2020
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase DomainSusanne Grunewald, Lillian R Klug, Thomas Mühlenberg, et al.
Pageof 25